Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Chinese Patent Office
UBS
Daiichi Sankyo
Cantor Fitzgerald
Queensland Health
Fuji
Julphar
Farmers Insurance
Federal Trade Commission

Generated: February 23, 2018

DrugPatentWatch Database Preview

EVOMELA Drug Profile

« Back to Dashboard

When do Evomela patents expire, and when can generic versions of Evomela launch?

Evomela is a drug marketed by Spectrum Pharms and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-six patent family members in fourteen countries.

The generic ingredient in EVOMELA is melphalan hydrochloride. There are twelve drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the melphalan hydrochloride profile page.
Summary for EVOMELA
International Patents:36
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 6
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:EVOMELA at DailyMed
Drug patent expirations by year for EVOMELA
Pharmacology for EVOMELA
Drug ClassAlkylating Drug
Mechanism of ActionAlkylating Activity

US Patents and Regulatory Information for EVOMELA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Spectrum Pharms EVOMELA melphalan hydrochloride POWDER;IV (INFUSION) 207155-001 Mar 10, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Spectrum Pharms EVOMELA melphalan hydrochloride POWDER;IV (INFUSION) 207155-001 Mar 10, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Spectrum Pharms EVOMELA melphalan hydrochloride POWDER;IV (INFUSION) 207155-001 Mar 10, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Spectrum Pharms EVOMELA melphalan hydrochloride POWDER;IV (INFUSION) 207155-001 Mar 10, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for EVOMELA
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Injection 50 mg/vial ➤ Subscribe 9/8/2017

Non-Orange Book US Patents for EVOMELA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,635,773 Sulfoalkyl ether cyclodextrin compositions ➤ Sign Up
9,750,822 Sulfoalkyl ether cyclodextrin compositions ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for EVOMELA

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Covington
QuintilesIMS
Julphar
Medtronic
McKinsey
Accenture
Harvard Business School
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot